Daniel R Simpson1, María Elena Martínez, Samir Gupta, Jona Hattangadi-Gluth, Loren K Mell, Gregory Heestand, Paul Fanta, Sonia Ramamoorthy, Quynh-Thu Le, James D Murphy. 1. Affiliations of authors: Center for Advanced Radiotherapy Technologies, Department of Radiation Medicine and Applied Science (DRS, JHG, LKM, JDM), Department of Family & Preventive Medicine (MEM), Division of Gastroenterology, Department of Internal Medicine (SG), Division of Hematology-Oncology (GH, PF), Department of Surgery (SR), Moores Cancer Center (DRS, MEM, SG, JHG, LKM, GH, PF, SR, JDM), University of California San Diego, La Jolla, California; San Diego Veterans Affairs Healthcare System, San Diego, California (SG); Department of Radiation Oncology, Stanford University, Stanford, California (QL).
Abstract
BACKGROUND: Black patients with metastatic colorectal cancer have inferior survival compared to white patients. The purpose of this study was to examine disparity in specialist consultation and multimodality treatment and the impact that treatment inequality has on survival. METHODS: We identified 9935 non-Hispanic white and 1281 black patients with stage IV colorectal cancer aged 66 years and older from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Logistic regression models identified race-based differences in consultation rates and subsequent treatment with surgery, chemotherapy, or radiation. Multivariable Cox regression models identified potential factors that explain race-based survival differences. All statistical tests were two-sided. RESULTS: Black patients had lower rates of consultation with surgery, medical oncology, and radiation oncology. Among patients seen in consultation, black patients received less surgery directed at the primary tumor, liver- or lung-directed surgery, chemotherapy, and radiotherapy. Unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients (hazard ratio [HR] = 1.15; 95% confidence interval (CI) = 1.08 to 1.22; P < .001). Adjustment for patient, tumor, and demographic variables marginally reduced the risk of death (HR = 1.08; 95% CI = 1.01 to 1.15; P = .03). After adjustment for differences in treatment, the increased risk of death for black patients disappeared. CONCLUSIONS: Our study shows racial disparity in specialist consultation as well as subsequent treatment with multimodality therapy for metastatic colorectal cancer, and it suggests that inferior survival for black patients may stem from this treatment disparity. Further research into the underlying causes of this inequality will improve access to treatment and survival in metastatic colorectal cancer.
BACKGROUND: Black patients with metastatic colorectal cancer have inferior survival compared to white patients. The purpose of this study was to examine disparity in specialist consultation and multimodality treatment and the impact that treatment inequality has on survival. METHODS: We identified 9935 non-Hispanic white and 1281 black patients with stage IV colorectal cancer aged 66 years and older from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. Logistic regression models identified race-based differences in consultation rates and subsequent treatment with surgery, chemotherapy, or radiation. Multivariable Cox regression models identified potential factors that explain race-based survival differences. All statistical tests were two-sided. RESULTS: Black patients had lower rates of consultation with surgery, medical oncology, and radiation oncology. Among patients seen in consultation, black patients received less surgery directed at the primary tumor, liver- or lung-directed surgery, chemotherapy, and radiotherapy. Unadjusted survival analysis found a 15% higher chance of dying for black patients compared with white patients (hazard ratio [HR] = 1.15; 95% confidence interval (CI) = 1.08 to 1.22; P < .001). Adjustment for patient, tumor, and demographic variables marginally reduced the risk of death (HR = 1.08; 95% CI = 1.01 to 1.15; P = .03). After adjustment for differences in treatment, the increased risk of death for black patients disappeared. CONCLUSIONS: Our study shows racial disparity in specialist consultation as well as subsequent treatment with multimodality therapy for metastatic colorectal cancer, and it suggests that inferior survival for black patients may stem from this treatment disparity. Further research into the underlying causes of this inequality will improve access to treatment and survival in metastatic colorectal cancer.
Authors: Craig C Earle; Peter J Neumann; Richard D Gelber; Milton C Weinstein; Jane C Weeks Journal: J Clin Oncol Date: 2002-04-01 Impact factor: 44.544
Authors: L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Arnold L Potosky; Linda C Harlan; Richard S Kaplan; Karen A Johnson; Charles F Lynch Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: Joan L Warren; Linda C Harlan; Angela Fahey; Beth A Virnig; Jean L Freeman; Carrie N Klabunde; Gregory S Cooper; Kevin B Knopf Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Beth A Virnig; Joan L Warren; Gregory S Cooper; Carrie N Klabunde; Nicola Schussler; Jean Freeman Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Kelsey Lau-Min; Preeti Prakash; Eunji Jo; Aaron P Thrift; Susan Hilsenbeck; Benjamin L Musher Journal: Clin Colorectal Cancer Date: 2020-01-02 Impact factor: 4.481
Authors: Alem A Belachew; Monica E Reyes; Yuanqing Ye; Gottumukkala S Raju; M Alma Rodriguez; Xifeng Wu; Michelle A T Hildebrandt Journal: Qual Life Res Date: 2020-07-03 Impact factor: 4.147
Authors: Elizabeth B Lamont; Richard L Schilsky; Yulei He; Hyman Muss; Harvey Jay Cohen; Arti Hurria; Ashley Meilleur; Hedy L Kindler; Alan Venook; Rogerio Lilenbaum; Harvey Niell; Richard M Goldberg; Steven Joffe Journal: J Natl Cancer Inst Date: 2014-11-27 Impact factor: 13.506
Authors: Mark A Lewis; Noura Sharabash; Zhi-Feng Miao; Lydia N Lyons; Jay Piccirillo; Donna Kallogjeri; Mario Schootman; Matthew Mutch; Yan Yan; Marc S Levin; Antoni Castells; Miriam Cuatrecasas; Jason C Mills; Zhen-Ning Wang; Deborah C Rubin Journal: Dig Dis Sci Date: 2017-11-01 Impact factor: 3.199
Authors: Tyler Hinshaw; Suzanne Lea; Justin Arcury; Alexander A Parikh; Rebecca A Snyder Journal: Cancer Causes Control Date: 2021-01-04 Impact factor: 2.506
Authors: Zaid M Abdelsattar; Sandra L Wong; Scott E Regenbogen; Diana M Jomaa; Karin M Hardiman; Samantha Hendren Journal: Cancer Date: 2016-01-25 Impact factor: 6.860